The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

Published Date: 08 Apr 2024

In three trials, the response rate was about half the patients, and it lasted for up to 19 months.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Novel biomarkers may improve diagnosis of gallbladder cancer

2.

Having dense breasts is linked to cancer, but advice about breast density can depend on where you live

3.

Screening for prostate cancer: is it time to give up digital rectal examination?

4.

Sarah Ferguson was identified as having malignant melanoma. These are the most recent therapies.

5.

Addition of regional nodal irradiation does not decrease rates of invasive breast cancer recurrence, study finds


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot